Latest Manufacturing Agreements News

Page 2 of 3
Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.
Ada Torres
Ada Torres
29 Jan 2026
Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.
Ada Torres
Ada Torres
28 Jan 2026
Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.
Ada Torres
Ada Torres
28 Jan 2026
Peak Processing has significantly expanded its manufacturing partnership with St. Peter’s Beverages, tripling its SKU production and boosting annual output by up to 700,000 units. This move strengthens its foothold in North America’s cannabis beverage market using proprietary technology.
Victor Sage
Victor Sage
23 Jan 2026
Pure Foods Tasmania has launched contract manufacturing with Brilliant Food Australia, marking a significant step in utilising its Woodbridge Smokehouse facility and expanding regional employment.
Victor Sage
Victor Sage
23 Jan 2026
SPC Global Holdings delivered a transformational FY25 with robust financial results and strategic international growth, setting the stage for a confident 25% EBITDA increase in FY26.
Victor Sage
Victor Sage
24 Nov 2025
Anteris Technologies Global Corp. reported a $22.2 million loss in Q3 2025 while progressing its DurAVR Transcatheter Heart Valve pivotal trial following key regulatory approvals. The company bolstered its cash position with a $25.2 million private placement post-quarter.
Ada Torres
Ada Torres
13 Nov 2025
BPH Global Limited secured $1.1 million in a recent placement and reported robust growth in its Indonesian seaweed operations, alongside promising advances in innovative seaweed-based products and strategic regional partnerships.
Ada Torres
Ada Torres
31 Oct 2025
Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.
Ada Torres
Ada Torres
29 Aug 2025
Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.
Ada Torres
Ada Torres
28 Aug 2025
Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.
Ada Torres
Ada Torres
31 July 2025
Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.
Ada Torres
Ada Torres
31 July 2025